Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00319683 · ClinicalTrials.gov registry record · Phase 1
A Study of ADH300004 and 5-Fluorouracil in Locally Advanced, Recurrent, or Metastatic Hepatocellular Carcinoma
A Phase 1 study, sponsored by Adherex Technologies.
- Terminated
- Registry status
- Phase 1
- Development phase
NCT00319683: Clinical Trial Phase 1 study, sponsored by Adherex Technologies.
NCT00319683 is a Phase 1 study that was terminated before completion, run by Adherex Technologies. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00319683, a Phase 1 study, was terminated before completion, sponsored by Adherex Technologies.
- TERMINATED
- Registry status
- Phase 1
- Development phase
Study Summary
5-fluorouracil (5-FU), one of the most actively investigated anti-cancer drugs, is rapidly inactivated by the enzyme dihydropyrimidine dehydrogenase (DPD). ADH300004 blocks DPD. This study will test the safety and effects of oral ADH300004 14 hours prior to oral 5-FU in subjects with locally advanced, recurrent, or metastatic hepatocellular carcinoma.
Interventions
- DRUG ADH300004
Trial Details
| Field | Value |
|---|---|
| Phase | Phase 1 |
Why NCT00319683 stopped before completion
NCT00319683 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which ADH300004 is the first listed.
NCT00319683 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00319683 about?
NCT00319683 is a clinical study titled "A Study of ADH300004 and 5-Fluorouracil in Locally Advanced, Recurrent, or Metastatic Hepatocellular Carcinoma". 5-fluorouracil (5-FU), one of the most actively investigated anti-cancer drugs, is rapidly inactivated by the enzyme dihydropyrimidine dehydrogenase (DPD). ADH300004 blocks DPD. This study will test the safety and effects of oral ADH300004 14 hours prior to oral 5-FU in subjects with locally advance...
What is the current status of trial NCT00319683?
This trial is currently terminated. It is a Phase 1 study.
What interventions are being tested in trial NCT00319683?
The interventions under investigation include: ADH300004 (DRUG).
Who is sponsoring clinical trial NCT00319683?
This trial is sponsored by Adherex Technologies, which has 6 total clinical trials registered on ClinicalTrials.gov.